Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog
Xuanyan Xu

Xuanyan Xu

Sr. Marketing Manager, Life Sciences Audience at Elsevier

Connect with Xuanyan Xu on LinkedIn
Follow Xuanyan Xu on Twitter
Website:

About the author: Seeing academic discoveries translated into life-changing applications is exciting--and, even more so, being a part of it. As a senior marketing manager for Life Sciences Audience, I bring a strong understanding of pharmaceutical industry needs, advancing technologies and customer insights to drive the product go-to-market strategy, planning and execution. Everything I write about here is geared towards issues that I deeply care about: open innovation, emerging approaches in data science and the evolving regulatory framework. Feel free to reach out to me about these topics. It is my desire to deliver my understanding and knowledge back to our communities.

Posts by Xuanyan Xu

Life science community shares research to combat coronavirus

Posted on February 13th, 2020 in Pharma R&D

After weeks of rising concern about the rapid spread of the coronavirus in China’s Wuhan province, on January 31 the World Health Organization (WHO) declared it a global health emergency. But the story of the coronavirus outbreak is about more than a health scare – it is a terribly sad human tragedy. Already (as of this writing) over 40,000 people have been infected and over 1,000 have died since the outbreak began in December, and it is children and the elderly who have suffered most.

(more…)

FDA report shows 2019 was a strong year for innovation

Posted on February 10th, 2020 in Pharma R&D

Source: FDA.gov

On January 2, 2020, the FDA released the CDER annual report, stating that 2019 was “another strong year for innovation and advances.” The FDA cleared 48 new drugs for market, making it the second most productive year in the last decade (2018 approved 59 drugs). But given the fact that the total number of submissions have gone down, and that the American government was shut down for a lengthy period at the beginning of the year, the FDA delivered an impressive result in 2019.

(more…)

New book illustrating disease pathways released

Posted on January 23rd, 2020 in Pharma R&D

Pathway models are critical to drug discovery and personalized medicine, as they help with analyzing the massive amounts of data and information that confront pharma researchers in today’s data-rich world. That’s why it’s more important than ever to gain a better understanding of molecular signaling biology and disease pathways. To that end, Elsevier has just published Disease Pathways: An Atlas of Human Disease Signaling Pathways.

(more…)

Dr. Anton Yuryev discusses pathways and precision medicine at PMWC

Posted on January 16th, 2020 in Pharma R&D

Why is pathway and molecular signaling critical for precision medicine? Dr. Anton Yuryev, Consulting Director of Professional Services at Elsevier, will be addressing that question and more in a presentation at the Precision Medicine World Conference in Silicon Valley this month.

(more…)

  1. 1
  2. 2
  3. 3
  4. 6